Full Text Journal Articles by
Author Margaret B Lucitt


Find full text journal articles

Current perspectives on the interleukin-1 family as targets for inflammatory disease.

Yasmina E Hernandez-Santana, Eirini Giannoudaki, Gemma Leon, Margaret B Lucitt, Patrick T Walsh,

Since the first description of interleukin-1 (IL-1) and the genesis of the field of cytokine biology, the understanding of how IL-1 and related cytokines play central orchestrating roles in the inflammatory response has been an area of intense investigation. As a consequence of these endeavours, specific strategies have been developed ... Read more >>

Eur J Immunol (European journal of immunology)
[2019, 49(9):1306-1320]

Cited: 2 times

View full text PDF listing >>

Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.

Robyn Bruen, Sean Curley, Sarina Kajani, Daniel Crean, Marcella E O'Reilly, Margaret B Lucitt, Catherine G Godson, Fiona C McGillicuddy, Orina Belton,

Macrophages play a pivotal role in atherosclerotic plaque development. Recent evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, can attenuate pro-inflammatory responses in macrophages. We hypothesized that liraglutide could limit atherosclerosis progression in vivo via modulation of the inflammatory response.Human THP-1 macrophages and bone marrow-derived macrophages, from both ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2017, 16(1):143]

Cited: 11 times

View full text PDF listing >>


Assaying the efficacy of dual-antiplatelet therapy: use of a controlled-shear-rate microfluidic device with a well-defined collagen surface to track dynamic platelet adhesion.

Margaret B Lucitt, Sinead O'Brien, Jonathan Cowman, Gerardene Meade, Lourdes Basabe-Desmonts, Martin Somers, Nigel Kent, Antonio J Ricco, Dermot Kenny,

We report the development and demonstration of an assay that distinguishes the pharmacological effects of two widely used antiplatelet therapies, aspirin (COX-1 inhibitor) and clopidogrel (P2Y12 inhibitor). Whole blood is perfused through a low-volume microfluidic device in contact with a well-characterized (ellipsometry, atomic force microscopy) acid-soluble type I collagen surface. ... Read more >>

Anal Bioanal Chem (Analytical and bioanalytical chemistry)
[2013, 405(14):4823-4834]

Cited: 6 times

View full text PDF listing >>

Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis.

Ying Yu, Margaret B Lucitt, Jane Stubbe, Yan Cheng, Ulla G Friis, Pernille B Hansen, Boye L Jensen, Emer M Smyth, Garret A FitzGerald,

Little is known about prostaglandin F(2alpha) in cardiovascular homeostasis. Prostaglandin F(2alpha) dose-dependently elevates blood pressure in WT mice via activation of the F prostanoid (FP) receptor. The FP is expressed in preglomerular arterioles, renal collecting ducts, and the hypothalamus. Deletion of the FP reduces blood pressure, coincident with a reduction ... Read more >>

Proc Natl Acad Sci U S A (Proceedings of the National Academy of Sciences of the United States of America)
[2009, 106(19):7985-7990]

Cited: 45 times

View full text PDF listing >>

EBP, a program for protein identification using multiple tandem mass spectrometry datasets.

Thomas S Price, Margaret B Lucitt, Weichen Wu, David J Austin, Angel Pizarro, Anastasia K Yocum, Ian A Blair, Garret A FitzGerald, Tilo Grosser,

MS/MS combined with database search methods can identify the proteins present in complex mixtures. High throughput methods that infer probable peptide sequences from enzymatically digested protein samples create a challenge in how best to aggregate the evidence for candidate proteins. Typically the results of multiple technical and/or biological replicate experiments ... Read more >>

Mol Cell Proteomics (Molecular & cellular proteomics : MCP)
[2007, 6(3):527-536]

Cited: 34 times

View full text PDF listing >>

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

Karine M Egan, Miao Wang, Susanne Fries, Margaret B Lucitt, Alicia M Zukas, Ellen Puré, John A Lawson, Garret A FitzGerald,

<h4>Background</h4>Antagonism or deletion of the receptor (the TP) for the cyclooxygenase (COX) product thromboxane (Tx)A2, retards atherogenesis in apolipoprotein E knockout (ApoE KO) mice. Although inhibition or deletion of COX-1 retards atherogenesis in ApoE and LDL receptor (LDLR) KOs, the role of COX-2 in atherogenesis remains controversial. Other products of ... Read more >>

Circulation (Circulation)
[2005, 111(3):334-342]

Cited: 121 times

View full text PDF listing >>


0.6319 s